FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200468809> ?p ?o ?g. }

• W4200468809 endingPage "253" @default.
• W4200468809 startingPage "245" @default.
• W4200468809 abstract "In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless of chemotherapy response or biomarker status. Here, we report exploratory analyses of the impact of homologous recombination deficient (HRD) or proficient (HRP) status on progression-free survival (PFS) and objective response rates during chemotherapy.Women with Stage III-IV ovarian carcinoma were randomized to veliparib-throughout, veliparib-combination-only, or placebo. Stratification factors included timing of surgery and germline BRCA mutation status. HRD status was dichotomized at genomic instability score 33. During combination therapy, CA-125 levels were measured at baseline and each cycle; radiographic responses were assessed every 9 weeks.Of 1140 patients randomized, 742 had BRCA wild type (BRCAwt) tumors (HRP, n = 373; HRD/BRCAwt, n = 329). PFS hazard ratios between veliparib-throughout versus control were similar in both BRCAwt populations (HRD/BRCAwt: 22.9 vs 19.8 months; hazard ratio 0.76; 95% confidence interval [CI] 0.53-1.09; HRP: 15.0 vs 11.5 months; hazard ratio 0.765; 95% CI 0.56-1.04). By Cycle 3, the proportion with ≥90% CA-125 reduction from baseline was higher in those receiving veliparib (pooled arms) versus control (34% vs 23%; P = 0.0004); particularly in BRCAwt and HRP subgroups. Complete response rates among patients with measurable disease after surgery were 24% with veliparib (pooled arms) and 18% with control.These results potentially broaden opportunities for PARPi utilization among patients who would not qualify for frontline PARPi maintenance based on other trials." @default.
• W4200468809 created "2021-12-31" @default.
• W4200468809 creator A5009234043 @default.
• W4200468809 creator A5021359849 @default.
• W4200468809 creator A5021894535 @default.
• W4200468809 creator A5022267430 @default.
• W4200468809 creator A5028931954 @default.
• W4200468809 creator A5033578335 @default.
• W4200468809 creator A5036444245 @default.
• W4200468809 creator A5046031005 @default.
• W4200468809 creator A5053606154 @default.
• W4200468809 creator A5054370710 @default.
• W4200468809 creator A5054602117 @default.
• W4200468809 creator A5056784491 @default.
• W4200468809 creator A5058244284 @default.
• W4200468809 creator A5063042904 @default.
• W4200468809 creator A5069337573 @default.
• W4200468809 creator A5081561534 @default.
• W4200468809 creator A5084007785 @default.
• W4200468809 creator A5084420374 @default.
• W4200468809 creator A5088826153 @default.
• W4200468809 date "2022-02-01" @default.
• W4200468809 modified "2023-10-17" @default.
• W4200468809 title "Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study" @default.
• W4200468809 cites W1761594004 @default.
• W4200468809 cites W1973268287 @default.
• W4200468809 cites W2002710053 @default.
• W4200468809 cites W2057706543 @default.
• W4200468809 cites W2081185709 @default.
• W4200468809 cites W2094666871 @default.
• W4200468809 cites W2106157865 @default.
• W4200468809 cites W2121415861 @default.
• W4200468809 cites W2131670056 @default.
• W4200468809 cites W2135915034 @default.
• W4200468809 cites W2163297822 @default.
• W4200468809 cites W2268198215 @default.
• W4200468809 cites W2279794621 @default.
• W4200468809 cites W2295085830 @default.
• W4200468809 cites W2323969866 @default.
• W4200468809 cites W2528228811 @default.
• W4200468809 cites W2557666746 @default.
• W4200468809 cites W2742502883 @default.
• W4200468809 cites W2754327139 @default.
• W4200468809 cites W2896626889 @default.
• W4200468809 cites W2897430921 @default.
• W4200468809 cites W2975141952 @default.
• W4200468809 cites W2976139792 @default.
• W4200468809 cites W2994977341 @default.
• W4200468809 cites W3014627414 @default.
• W4200468809 doi "https://doi.org/10.1016/j.ygyno.2021.12.003" @default.
• W4200468809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34906376" @default.
• W4200468809 hasPublicationYear "2022" @default.
• W4200468809 type Work @default.
• W4200468809 citedByCount "9" @default.
• W4200468809 countsByYear W42004688092022 @default.
• W4200468809 countsByYear W42004688092023 @default.
• W4200468809 crossrefType "journal-article" @default.
• W4200468809 hasAuthorship W4200468809A5009234043 @default.
• W4200468809 hasAuthorship W4200468809A5021359849 @default.
• W4200468809 hasAuthorship W4200468809A5021894535 @default.
• W4200468809 hasAuthorship W4200468809A5022267430 @default.
• W4200468809 hasAuthorship W4200468809A5028931954 @default.
• W4200468809 hasAuthorship W4200468809A5033578335 @default.
• W4200468809 hasAuthorship W4200468809A5036444245 @default.
• W4200468809 hasAuthorship W4200468809A5046031005 @default.
• W4200468809 hasAuthorship W4200468809A5053606154 @default.
• W4200468809 hasAuthorship W4200468809A5054370710 @default.
• W4200468809 hasAuthorship W4200468809A5054602117 @default.
• W4200468809 hasAuthorship W4200468809A5056784491 @default.
• W4200468809 hasAuthorship W4200468809A5058244284 @default.
• W4200468809 hasAuthorship W4200468809A5063042904 @default.
• W4200468809 hasAuthorship W4200468809A5069337573 @default.
• W4200468809 hasAuthorship W4200468809A5081561534 @default.
• W4200468809 hasAuthorship W4200468809A5084007785 @default.
• W4200468809 hasAuthorship W4200468809A5084420374 @default.
• W4200468809 hasAuthorship W4200468809A5088826153 @default.
• W4200468809 hasBestOaLocation W42004688091 @default.
• W4200468809 hasConcept C104317684 @default.
• W4200468809 hasConcept C121608353 @default.
• W4200468809 hasConcept C126322002 @default.
• W4200468809 hasConcept C141071460 @default.
• W4200468809 hasConcept C143998085 @default.
• W4200468809 hasConcept C182979987 @default.
• W4200468809 hasConcept C207103383 @default.
• W4200468809 hasConcept C2776694085 @default.
• W4200468809 hasConcept C2779138821 @default.
• W4200468809 hasConcept C2780427987 @default.
• W4200468809 hasConcept C2781312401 @default.
• W4200468809 hasConcept C44249647 @default.
• W4200468809 hasConcept C54355233 @default.
• W4200468809 hasConcept C71924100 @default.
• W4200468809 hasConcept C82381507 @default.
• W4200468809 hasConcept C86803240 @default.
• W4200468809 hasConceptScore W4200468809C104317684 @default.
• W4200468809 hasConceptScore W4200468809C121608353 @default.
• W4200468809 hasConceptScore W4200468809C126322002 @default.
• W4200468809 hasConceptScore W4200468809C141071460 @default.
• W4200468809 hasConceptScore W4200468809C143998085 @default.

• next